An early-stage fail highlights ongoing ALS drug development challenges, despite recent Biogen OK

Max Gelman

Senior Editor

A Takeda partner reported an early-stage ALS trial failure Tuesday morning and opted to discontinue the program entirely, serving as a reminder that despite two …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

An early-stage fail highlights ongoing ALS drug development challenges, despite recent Biogen OK

Max Gelman

Senior Editor

Sign up to read this article for free.

J&J partners on STAT6; AstraZeneca, Daiichi withdraw lung cancer drug EMA app

FDA approves subcutaneous version of Bristol Myers' Opdivo

BioNTech settles with NIH, UPenn in Covid vaccine disputes and will pay royalties

Sofinnova outlines $550M fund after IPOs and M&A deals

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

WuXi AppTec will sell cell and gene therapy business to private equity firm

An ear­ly-stage fail high­lights on­go­ing ALS drug de­vel­op­ment chal­lenges, de­spite re­cent Bio­gen OK

Max Gelman

Senior Editor

Sign up to read this article for free.

more like this

J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

An early-stage fail highlights ongoing ALS drug development challenges, despite recent Biogen OK

J&J partners on STAT6; AstraZeneca, Daiichi withdraw lung cancer drug EMA app

FDA approves subcutaneous version of Bristol Myers' Opdivo

BioNTech settles with NIH, UPenn in Covid vaccine disputes and will pay royalties

Sofinnova outlines $550M fund after IPOs and M&A deals

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

WuXi AppTec will sell cell and gene therapy business to private equity firm